3645 results for «566»
3645 results
Navigating the complexity of high bleeding risk
20 May 2026 – From EuroPCR 2026
Focusing on patients with high bleeding risk undergoing PCI, this session presents contemporary evidence on prevalence, procedural strategies with different stent types, antiplatelet therapy considerations including diabetic and sex-specific outcomes, and novel technologies such as sirolimus-coated balloons and machine learning models for restenosis prediction.
When the angiogram shows no answer for your AMI patient: what's next?
20 May 2026 – From EuroPCR 2026
This session focuses on non-occlusive causes of acute coronary syndromes (ACS) when angiograms do not reveal clear pathology. It emphasizes the diagnostic value of intracoronary imaging for conditions such as MINOCA and spontaneous coronary artery dissection (SCAD), and discusses optimal treatment strategies and prognostic considerations.
Stentless PCI, DCB and BVS in complex scenarios
20 May 2026 – From EuroPCR 2026
This session explores the use of stentless percutaneous coronary interventions (PCI) employing drug-coated balloons (DCB) and bioresorbable scaffolds (BVS) in complex coronary scenarios. Through detailed case discussions, it addresses decision-making processes, technical considerations, and practical tips for successfully completing PCI without permanent stenting.
DCB - Going beyond in-stent restenosis
20 May 2026 – From EuroPCR 2026
This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
